Role of melanoma-associated antigens

From Melanocytes to Melanoma: The Progression to Malignancy

Volumn , Issue , 2006, Pages 619-631

  Gupta, Rishab K ^a   McElrath Garza, Ana M ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

immunotherapy; Melanoma; melanoma associated antigens; TA90; tumor associated antigens

Indexed keywords

EID: 84891415949     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-994-3_35     Document Type: Chapter

References (109)

1. Barnetson RS, Halliday GM. Regression in skin tumours: a common phenomenon. Australas J Dermatol 1997;38:S63-S65.
2. Printz C. Spontaneous regression of melanoma may offer insight into cancer immunology. J Natl Cancer Inst 2001;93:1047-1048.
3. Cochran AJ, Diehl V, Stjernsward J. Regression of primary malignant melanoma associated with a good prognosis despite metastasis to lymph nodes. Rev Eur Etud Clin Biol 1970;15:969-972.
4. Morton DL, Eilber FR, Malmgren RA, et al. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970;68:158-164.
5. Morton DL, Malmgren RA, Holmes EC, et al. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 1968;64:233-240.
6. Summer WC, Foraker AG. Spontaneous regression of human melanoma: clinical and experimental studies. Cancer 1960;13:79-81.
7. Movassagh M, Spatz A, Davoust J, et al. Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of meta-static dissemination in melanoma. Cancer Res 2004;64:2192-2198.
8. Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996;74:43-47.
9. Hersey P, Murray E, Grace J, McCarthy WH. Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma. Pathology 1985;17:385-391.
10. Steiner A, Wolf C, Pehamberger H, Wolff K. Late metastases of cutaneous malignant melanoma. Br J Dermatol 1986;114:737-740.
11. Koh HK, Sober AJ, Fitzpatrick TB. Late recurrence (beyond ten years) of cutaneous malignant melanoma. Report of two cases and a review of the literature. JAMA 1984;251:1859-1862.
12. Lejeune FJ. The impact of surgery on the course of melanoma. Recent Results Cancer Res 2002;160:151-157.
13. Shields JD, Borsetti M, Rigby H, et al. Lymphatic density and metastatic spread in human malignant melanoma. Br J Cancer 2004;90:693-700.
14. Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer 2003;98:413-423.
15. Fallowfield ME, Cook MG. Lymphatics in primary cutaneous melanoma. Am J Surg Pathol 1990;14:370-374.
16. Griffiths JD. Circulating cancer cells in surgery. Lond Clin Med J 1966;7:65-71.
17. Roberts SS, Cole WH. Cancer cells in the circulating blood. Semin Int 1961;10:2-10.
18. Keilholz U, Goldin-Lang P, Bechrakis NE, et al. Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-poly-merase chain reaction. Clin Cancer Res 2004;10:1605-1612.
19. Mocellin S, Del Fiore P, Guarnieri L, et al. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer 2004;111:741-745.
20. Palmieri G, Ascierto PA, Perrone F, et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol 2003;21:767-773.
21. Tsubura E, Yamashita T, Sone S. Inhibition of the arrest of hematogenously disseminated tumor cells. Cancer Metastasis Rev 1983;2:223-237.
22. Morton DL, Sparks FC, Haskell CM. Oncology. In: Swartz SI, Shire CT, Spencer FC, Storer EH, eds. Principles of Surgery, 3rd ed. McGraw Hill, New York, NY: 1979.
23. Vile RG, Chong H, Dorudi S. The immunosurveillance of cancer. In: Tumor Immunology: Immuno-therapy and Cancer Vaccines. Dalgleish AG, Browning M, eds. Cambridge University Press, Cambridge, UK: 1996.
24. Wang RF. Human tumor antigens: implications for cancer vaccine development. J Mol Med 1999;77:640-655.
25. Faries MB, Morton DL. Melanoma: is immunotherapy of benefit? Adv Surg 2003;37:139-169.
26. Morton DL, Ollila DW, Hsueh EC, Essner R, Gupta RK. Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J Clin 1999;49:101-116.
27. Bitton RJ. Cancer vaccines: a critical review on clinical impact. Curr Opin Mol Ther 2004;6:17-26.
28. Pawelec G. Tumor escape: anti-tumor effectors too much of a good thing? Cancer Immunol Immunother 2004;53:262-274.
29. Parkhurst MR, Riley JP, Robbins PF, Rosenberg SA. Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein. J Immunother 2004;27:79-91.
30. Mandic M, Almunia C, Vicel S, et al. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells. Cancer Res 2003;63:6506-6515.
31. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 1996;6:11-24.
32. Schwartz RH. Acquisition of immunologic self-tolerance. Cell 1989;57:1073-1081.
33. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989;54 Pt 1:1-13.
34. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-1102.
35. Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 2003;22:3180-3187.
36. Coulie PG, Lehmann F, Lethe B, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995;92:7976-7980.
37. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-719.
38. Mukherji B, MacAlister TJ. Clonal analysis of cytotoxic T cell response against human melanoma. J Exp Med 1983;158:240-245.
39. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647.
40. De Plaen E, Arden K, Traversari C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994;40:360-369.
41. Coulie PG. Human tumor antigens recognized by cytolytic T lymphocytes. In: Tumor Immunology: Immunotherapy and Cancer Vaccines. Cambridge University Press, New York, NY: 1996, pp. 95-125.
42. Zuber M, Spagnoli GC, Kocher T, et al. Heterogeneity of melanoma antigen-1 (MAGE-1) gene and protein expression in malignant melanoma. Eur Surg Res 1997;29:403-410.
43. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-698.
44. Brasseur F, Rimoldi D, Lienard D, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995;63:375-80.
45. Dalerba P, Ricci A, Russo V, et al. High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies. Int J Cancer 1998;77:200-204.
46. Kawakami Y, Rosenberg SA. Human tumor antigens recognized by T-cells. Immunol Res 1997;16:313-339.
47. Murer K, Urosevic M, Willers J, et al. Expression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patients. Melanoma Res 2004; 14:257-262.
48. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-685.
49. Lotz C, Ferreira EA, Drexler I, et al. Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man. Int J Cancer 2004;108:571-579.
50. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996;184:2207-2216.
51. Bakker AB, Schreurs MW, de Boer AJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994;179:1005-1009.
52. Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. Exp Med 1990;171:1375-1380.
53. Harada M, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells. Cancer Res 2001;61:1089-1094.
54. Houghton AN, Vijayasardhi S, Bouchard B, Nazftzger C, Hara I, Chapman PB. Recognition of autoantigens by patients with melanoma. Ann NY Acad Sci 1993;690:59-68.
55. Johansson M, Takasaki A, Lenner L, Arstrand K, Kagedal B. Quantitative relationships between pigment-related mRNA and biochemical melanoma markers in melanoma cell lines. Melanoma Res 2002;12:193-200.
56. Slingluff CL Jr, Colella TA, Thompson L, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother 2000;48:661-672.
57. Wolchok JD, Weber JS, Houghton AN, Livingston PO. Melanoma vaccines. In: Balch CM, Houghton AN, Sober AJ, Soong SJ, eds. Cutaneous Melanoma, 4th ed. Quality Medical Publishing, St Louis, MO: 2003.
58. Bar-Dayan Y, Barshack I, Blank M, et al. Antibodies to the cytoplasm, cell membrane and nuclear membrane of malignant neoplasms in pooled normal human polyspecific immunoglobulin G. Int J Oncol 1999;15:1091-1096.
59. Thomas PJ, Kaur JS, Aitcheson CT, Robinson WA, Tan EM. Antinuclear, antinucleolar, and anticytoplasmic antibodies in patients with malignant melanoma. Cancer Res 1983;43:1372-1380.
60. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11, 810-11, 813.
61. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94:1914-1918.
62. Tureci O, Sahin U, Zwick C, Koslowski M, Seitz G, Pfreundschuh M. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci USA 1998;95:5211-5216.
63. Scanlon MJ, Simpson AJG, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immunity 2004;4:1-15.
64. Old LJ. Cancer Vaccine Collaborative 2002: opening address. Cancer Immun 2003;3:1.
65. Natali PG, Wilson BS, Imai K, Bigotti A, Ferrone S. Tissue distribution, molecular profile, and shedding of a cytoplasmic antigen identified by the monoclonal antibody 465.12S to human melanoma cells. Cancer Res 1982;42:583-589.
66. Euhus DM, Gupta RK, Morton DL. Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 1989;29:247-254.
67. Gupta RK, Morton DL. Clinical significance of tumor-associated antigens and antitumor antibodies in human malignant melanoma. In: Reisfeld RA, Ferrone S, eds. Melanoma Antigens and Antibodies. Plenum, New York, NY: 1982, pp. 139-172
68. Houghton AN, Wolchok JD. Immunology. In: Balch CH, Sober AJ, Soon SJ, eds. Cutaneous Melanoma. Quality Medical Publishing, St. Louis, MO. 2003 pp. 659-668.
69. Albino AP, Sozzi G, Nanus DM, Jhanwar SC, Houghton AN. Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene 1992;7: 2315-2321.
70. Ravindranath MH, Tuchida T, Irie RF. Diversity of ganglioside expression in human melanoma: In: Oettgen HF, ed. Gangliosides and Cancer. VCH Publishers, New York, NY: 1989, pp 80-91.
71. Ravindranath MH, Gonzales AM, Nishimoto K, Tam WY, Soh D, Morton DL. Immunology of gangliosides. Indian J Exp Biol 2000;38:301-312.
72. Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-1044.
73. Ravindranath MH, Morton DL. Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines. Cancer Invest 1997;15:491-499.
74. Kageshita T, Hirai S, Kimura T, Hanai N, Ohta S, Ono T. Association between sialyl Lewis(a) expression and tumor progression in melanoma. Cancer Res 1995;55:1748-1751.
75. Li J, Pereira S, Van Belle P, et al. Isolation of the melanoma-associated antigen p23 using antibody phage display. J Immunol 2001;166:432-438.
76. Cai X, Garen A. Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proc Natl Acad Sci USA 1995;92:6537-6541.
77. Kupsch JM, Tidman NH, Kang NV, et al. Isolation of human tumor-specific antibodies by selection of an antibody phage library on melanoma cells. Clin Cancer Res 1999;5:925-931.
78. Desai SA, Wang X, Noronha EJ, Kageshita T, Ferrone S. Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library. Cancer Res 1998;58:2417-2425.
79. Hanahan D, Lanzavecchia A, Mihich E. Fourteenth Annual Pezcoller Symposium: the novel dichotomy of immune interactions with tumors. Cancer Res 2003;63:3005-3008.
80. Belardelli F, Ferrantini M, Parmiani G, Schlom J, Garaci E. International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res 2004;64:6827-6830.
81. Cormier JN, Hijazi YM, Abati A, et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998;75:517-524.
82. Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 2004;27:184-190.
83. Radford KJ, Mallesch J, Hersey P. Suppression of human melanoma cell growth and metastasis by the melanoma-associated antigen CD63 (ME491). Int J Cancer 1995;62:631-635.
84. Kondoh M, Ueda M, Ichihashi M, Mishima Y. Decreased expression of human melanoma-associated antigen ME491 along the progression of melanoma pre-canceroses to invasive and metastatic melanomas. Melanoma Res 1993;3:241-245.
85. Hoek K, Rimm DL, Williams KR, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004;64:5270-5282.
86. Du J, Miller AJ, Widlund HR, Horstmann MA, Ramaswamy S, Fisher DE. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol 2003;163:333-343.
87. Durda PJ, Dunn IS, Rose LB, et al. Induction of "antigen silencing" in melanomas by oncostatin M: down-modulation of melanocyte antigen expression. Mol Cancer Res 2003;1:411-419.
88. Merimsky O, Shoenfeld Y, Chaitchik S, Yecheskel G, Fishman P. Antigens and antibodies in malignant melanoma. Tumour Biol 1994;15:188-202.
89. Ramirez-Montagut T, Andrews DM, Ihara A, et al. Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1. Clin Exp Immunol 2000;119:11-18.
90. Merimsky O, Shoenfeld Y, Yecheskel G, Chaitchik S, Azizi E, Fishman P. Vitiligo-and melanoma-associated hypopigmentation: a similar appearance but a different mechanism. Cancer Immunol Immunother 1994;38:411-416.
91. Rote NS, Gupta RK, Morton DL. Tumor-associated antigens detected by autologous sera in urine of patients with solid neoplasms. J Surg Res 1980;29:18-22.
92. Rote NS, Gupta RK, Morton DL. Determination of incidence and partial characterization of tumor-associated antigens found in the urine of patients bearing solid tumors. Int J Cancer 1980;26:203-210.
93. Euhus DM, Gupta RK, Morton DL. Characterization of a 90-100 kDa tumor-associated antigen in the sera of melanoma patients. Int J Cancer 1990;45:1065-1070.
94. Kelley MC, Jones RC, Gupta RK, et al. Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma. Cancer 1998;83:1355-1361.
95. Litvak DA, Gupta RK, Yee R, Wanek LA, Ye W, Morton DL. Endogenous immune response to early-and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors. J Am Coll Surg 2004;198:227-235.
96. Hsueh EC, Gupta RK, Yee R, Leopoldo ZC, Qi K, Morton DL. Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma? Ann Surg Oncol 2000; 7:232-238.
97. Euhus DM, Gupta RK, Morton DL. Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 1989;29:247-254.
98. Jones RC, Kelley MC, Gupta RK, et al. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Ann Surg Oncol 1996;3:437-445.
99. Chung MH, Gupta RK, Hsueh E, et al. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J Clin Oncol 2003;21:313-319.
100. DiFronzo LA, Gupta RK, Essner R, et al. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 2002;20:3242-3248.
101. Hsueh EC, Gupta RK, Qi K, Morton DL. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998;16:2913-2920.
102. Wong JH, Gupta RK, Morton DL. Serial determinations of melanoma tumor-associated antigen and antibody in patients with stage I melanoma. Arch Surg 1986;121:1342-1345.
103. Euhus DM, Gupta RK, Morton DL. Detection of a tumor-associated glycoprotein antigen in serum and urine of melanoma patients by murine monoclonal antibody (AD1-40F4) in enzyme immunoas-say. J Clin Lab Anal 1989;3:184-190.
104. Euhus DM, Gupta RK, Morton DL. Association between allo-immunoreactive and xeno-immunore-active subunits of a glycoprotein tumor-associated antigen. Cancer Immunol Immunother 1990;32:214-220.
105. Gupta RK, Morton DL. Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated-antigen specific immune complexes in cancer patients. J Clin Lab Anal 1992;6:329-336.
106. Chung MH, Gupta RK, Essner R, Ye W, Yee R, Morton DL. Serum TA90 immune complex assay can predict outcome after resection of thick (> or =4 mm) primary melanoma and sentinel lym-phadenectomy. Ann Surg Oncol 2002;9:120-126.
107. Kelley MC, Gupta RK, Hsueh EC, Yee R, Stern S, Morton DL. Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma. J Clin Oncol 2001;19:1176-1182.
108. Hsueh EC, Gupta RK, Qi K, Yee R, Leopoldo ZC, Morton DL. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma. Cancer J Sci Am 1997;3:364-370.
109. Halliday GM. Skin immunity and melanoma development. In: Thompson JF, Morton DL, Kroon BR, eds. Textbook of Melanoma. Martin Dunitz, Taylor and Francis Group, New York, NY: 2004, pp. 25-42.